clinical trial · NCT07228078
Open-Label Extension Protocol to SNK01-AD01 Study
NKGen Biotech, Inc.·phase2·recruiting·n = 30
Alzheimer DiseaseSNK01
brief summary
Open-Label Extension Protocol to SNK01-AD01 Study
started
Jun 30, 2025
primary completion
Apr 1, 2028
completion
Apr 1, 2028
last updated
Nov 13, 2025
detailed description
Open-label extension study to assess long-term safety and tolerability of SNK01 administered as an intravenous (IV) infusion every 3 weeks in participants with Alzheimer's Disease
official title
An Open-Label Extension (OLE) Study to Evaluate the Long-Term Safety, Tolerability and Exploratory Efficacy of SNK01 in Participants With Alzheimer's Disease (Study SNK01-AD02)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol